

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/014,156	12/07/2001	Douglas James Hilton	11268A	7385
7590 10/03/2003 Scully, Scott, Murphy & Presser			EXAMINER	
			ULM, JOHN D	
400 Garden City Plaza Garden City, NY 11530			ART UNIT	PAPER NUMBER
•			1646	
			DATE MAILED: 10/03/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
Office Action Summary		10/014,156	HILTON ET AL.
		Examiner	Art Unit
		John D. Ulm	1646
Period fe	The MAILING DATE of this communication or Reply	appears on the cover sheet wi	th the correspondence address
THE - Externation - If the - If NC - Failu - Any	MORTENED STATUTORY PERIOD FOR RE MAILING DATE OF THIS COMMUNICATIO ensions of time may be available under the provisions of 37 CFr SIX (6) MONTHS from the mailing date of this communication, e period for reply specified above is less than thirty (30) days, a period for reply is specified above, the maximum statutory peure to reply within the set or extended period for reply will, by stareply received by the Office later than three months after the med patent term adjustment. See 37 CFR 1.704(b).	N. R 1.136(a). In no event, however, may a really within the statutory minimum of thirt riod will apply and will expire SIX (6) MON atute, cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).
1)[	Responsive to communication(s) filed on 2	<u>12/07/2001</u> .	
2a)[_	This action is <b>FINAL</b> . 2b)⊠	This action is non-final.	
3) <u></u> Disposit	Since this application is in condition for alle closed in accordance with the practice und ion of Claims		
4)	Claim(s) 6-11 and 15-29 is/are pending in	the application.	
	4a) Of the above claim(s) is/are without	drawn from consideration.	
5)	Claim(s) is/are allowed.		
6)	Claim(s) is/are rejected.		
7)	Claim(s) is/are objected to.		
8)⊠	Claim(s) 6-11 and 15-29 are subject to rest	riction and/or election require	ment.
Applicat	ion Papers		
9)[	The specification is objected to by the Exam	niner.	
10)	The drawing(s) filed on is/are: a) ac	ccepted or b) objected to by the	ne Examiner.
_	Applicant may not request that any objection to	- · · · · · · · · · · · · · · · · · · ·	• •
11)	The proposed drawing correction filed on		isapproved by the Examiner.
> []	If approved, corrected drawings are required in		
•	The oath or declaration is objected to by the	Examiner.	
-	under 35 U.S.C. §§ 119 and 120		
	Acknowledgment is made of a claim for fore	eign priority under 35 U.S.C. §	3 119(a)-(d) or (f).
a)	☐ All b)☐ Some * c)☐ None of:		
	1. Certified copies of the priority docume		
	2. Certified copies of the priority docume		
* 5	<ol> <li>Copies of the certified copies of the p application from the International</li> <li>See the attached detailed Office action for a</li> </ol>	Bureau (PCT Rule 17.2(a)).	-
	Acknowledgment is made of a claim for dome	•	
а	a)	provisional application has be	een received.
Attachmen			
2) 🔲 Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s	5) Notice of Ir	Summary (PTO-413) Paper No(s) nformal Patent Application (PTO-152)

Application/Control Number: 10/014,156

Art Unit: 1646

Claims 6 to 11 and 15 to 29 are pending in the instant application. Claims 1 to 5 and 12 to 14 were canceled and claims 23 to 29 have been added as requested by Applicant in the correspondence of 07 December of 2001.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 6 to 11, 20, 23, 24 and 28, drawn to a recombinant leptin receptor, classified in class 530, subclass 350.
- II. Claims 15, 16, 25 and 26, drawn to an antibody to a leptin receptor, classified in class 530, subclass 388.22.
- III. Claims 17, 18 and 21, drawn to a ligand, classified in class 530, subclass 399.
- IV. Claims 19 and 27, drawn to a binding assay, classified in class 435, subclass 7.21.
- V. Claims 22 and 29, drawn to a method of treatment by administering a receptor protein, classified in class 514, subclass 2.

The inventions are distinct, each from the other because of the following reasons:

The receptor protein of invention I, the antibody of invention II and the ligand of invention III are three chemically distinct and structurally unrelated compounds each of which can be made and used without the others. These three compounds lack unity of invention because they do not have a common utility that is based upon a shared feature or combination of features lacking from the prior art.

Invention I is related to each of inventions IV and V as product and process of use. The inventions can be shown to be distinct if either or both of the following can be

Application/Control Number: 10/014,156

Art Unit: 1646

shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the analytical method of invention IV and the method of treatment that is invention V are two materially different methods of using the protein of invention I because they achieve different objectives through different method steps.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (703) 308-4008. The examiner can normally be reached on Monday through Friday from 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached at (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242 or (703) 872-9306. Official responses under 37 C.F.R. § 1.116 should be directed to (703) 872-9307.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Application/Control Number: 10/014,156

Art Unit: 1646

Page 4

JOHN ULM PRIMARY EXAMINER GROUP 1800